
|Articles|March 4, 2022
Daily Medication Pearl: Upadacitinib (Rinvoq)
Author(s)Saro Arakelians, PharmD
Advertisement
Medication Pearl of the Day: Upadacitinib (Rinvoq)
Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.
Insight:
- Dosing: The recommended dosage of Rinvoq is 15 mg once daily.
- Dosage forms: Extended-release tablets 15 mg and 30 mg.
- Adverse events: Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.
- Mechanism of action: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
- Manufacturer: AbbVie
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
5





































































































